These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1162 related items for PubMed ID: 29270745

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K, Yu X, Wang H, Huang Z, Xu Y, Gong L, Fan Y.
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [Abstract] [Full Text] [Related]

  • 7. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 8. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z, Xie D, Su H, Lin B, Zhao L, Deng X, Chen H, Fei S, Jin X, Xie C.
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
    Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Huang KT, Chen HC, Lin MC.
    Lung Cancer; 2016 Mar; 93():47-54. PubMed ID: 26898614
    [Abstract] [Full Text] [Related]

  • 11. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
    Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.
    Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [Abstract] [Full Text] [Related]

  • 14. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, Luo Y, Tang W.
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [Abstract] [Full Text] [Related]

  • 15. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
    Fukihara J, Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Hasegawa Y.
    Oncology; 2014 Jan; 86(2):86-93. PubMed ID: 24457318
    [Abstract] [Full Text] [Related]

  • 16. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q.
    Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
    [Abstract] [Full Text] [Related]

  • 17. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z, Zhang Y.
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [Abstract] [Full Text] [Related]

  • 18. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A, Nissen PH, Jakobsen KR, Demuth C, Sorensen BS, Meldgaard P.
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [Abstract] [Full Text] [Related]

  • 19. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N.
    BMC Cancer; 2018 Jan 02; 18(1):6. PubMed ID: 29291705
    [Abstract] [Full Text] [Related]

  • 20. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
    Okuma Y, Kashima J, Watanabe K, Homma S.
    J Cancer Res Clin Oncol; 2018 Aug 02; 144(8):1601-1611. PubMed ID: 29858682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.